pharma · Severe, Refractory Systemic Lupus Erythematosus · Refractory Progressive Multiple Sclerosis · AUTL
Autolus
Autolus GmbH
Tubulis is a pharma organization headquartered in Munich, DE. It trades on NYSE under ticker AUTL. Primary therapeutic focus areas include Severe, Refractory Systemic Lupus Erythematosus, Refractory Progressive Multiple
Munich, Bayern 81377, DE HQ
117 Employees
Public company Type
AUTL · NYSE Ticker
Company details
- Status
- Public
- HQ
- Munich, Bayern 81377, DE
- Employees
- 117
- Programs
- 16
- Drugs
- 17
- Patents
- 49
AUTO CAR T cell therapy
Phase 2 · mab · Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
AUTO CAR T cell therapy for Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy is a Phase 2 program (mab) at Autolus GmbH with 1 ClinicalTrials.gov record(s).
Internal code AUTO-LT1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Autolus GmbH
- Phase
- Phase 2
- Modality
- mab
- Indication
- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
- Status
- active
- Trials
- 1